RTP Mobile Logo
Thyroid Cancer Update, Issue 1, 2010
Released October 2010

Featuring interviews with Drs Ezra EW Cohen and Marcia S Brose. (Audio Content)

CE Disclosures and Faculty Information


    Emerging clinical trial data on the management of differentiated and medullary thyroid cancer have been sparse during the past few decades. However, recent breakthroughs in the understanding of the pathogenesis of this type of cancer have led to the development of a number of innovative clinical protocols and ongoing clinical trials. It is hoped that recent and anticipated results from these trials will lead to the emergence and approval of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Thyroid Cancer Update uses one-on-one conversations with leading oncology investigators discussing the interdisciplinary management of thyroid cancer. By providing access to the latest research developments and expert perspectives on the disease, this CME program assists medical oncologists in the formulation of up-to-date clinical management strategies.


    • Apply the results of emerging research to effectively integrate novel tyrosine kinase inhibitors (TKIs) into the management of well-differentiated thyroid carcinoma.
    • Evaluate the implications of clinical data on thyroid cancer recently presented at the 2010 ASCO Annual Meeting, and incorporate these data into management strategies in the metastatic and relapsed settings.
    • Describe the ongoing trials investigating the safety and efficacy of multikinase inhibitor therapy for patients with advanced, well-differentiated thyroid carcinoma or medullary carcinoma of the thyroid.
    • Recall the prognostic significance of RET gene mutations in medullary carcinoma of the thyroid.
    • Recognize the adverse events associated with a longer duration of TKI therapy in thyroid carcinoma.
    • Counsel appropriately selected patients with thyroid cancer about the availability of ongoing clinical trials.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains an audio component. The participant should listen to the audio MP3s.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr CohenConsulting Agreements: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Lilly USA LLC; Speakers Bureau: Bristol-Myers Squibb Company. Dr Brose Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Onyx Pharmaceuticals Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from AstraZeneca Pharmaceuticals LP and Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2010
    Expiration date: October 2011

Acknowledge and close

Thyroid Cancer Update, Issue 1, 2010
Released October 2010

Featuring interviews with Drs Ezra EW Cohen and Marcia S Brose. (Audio Content)